Miricorilant

Overview

Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Evaluation of Miricorilant on Liver Fat in Patients With MASLD	2025/04/27	NCT06947304	Phase 1	Not yet recruiting	Corcept Therapeutics
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)	2023/10/30	NCT06108219	Phase 2	Recruiting	Corcept Therapeutics
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant	2023/02/03	NCT05712265	Phase 1	Completed	Corcept Therapeutics
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant	2022/09/23	NCT05553470	Phase 1	Completed	Corcept Therapeutics
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)	2021/11/11	NCT05117489	Phase 1	Completed	Corcept Therapeutics
Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants	2020/12/17	NCT04672499	Phase 1	Completed	Corcept Therapeutics
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo	2020/07/10	NCT04466215	Phase 2	Completed	The Scripps Research Institute
The Effect of CORT118335 on Olanzapine-Induced Weight Gain	2019/03/15	NCT03877562	Phase 1	Completed	Corcept Therapeutics
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)	2019/01/30	NCT03823703	Phase 2	Terminated	Corcept Therapeutics
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.	2019/01/28	NCT03818256	Phase 2	Completed	Corcept Therapeutics

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access